Bridgewater Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.7M | Sell |
241,689
-167,203
| -41% | -$9.75M | 0.07% | 204 |
|
|
2025
Q4 | $22.1M | Sell |
408,892
-35,140
| -8% | -$1.69M | 0.08% | 186 |
|
|
2025
Q3 | $20M | Sell |
444,032
-2,259,692
| -84% | -$106M | 0.08% | 199 |
|
|
2025
Q2 | $125M | Buy |
2,703,724
+362,486
| +15% | +$17.8M | 0.5% | 45 |
|
|
2025
Q1 | $143M | Buy |
2,341,238
+280,162
| +14% | +$16.3M | 0.66% | 37 |
|
|
2024
Q4 | $117M | Buy |
2,061,076
+1,450,718
| +238% | +$81.1M | 0.53% | 33 |
|
|
2024
Q3 | $31.6M | Buy |
610,358
+55,364
| +10% | +$2.6M | 0.18% | 112 |
|
|
2024
Q2 | $23M | Sell |
554,994
-148,232
| -21% | -$6.63M | 0.12% | 139 |
|
|
2024
Q1 | $38.1M | Sell |
703,226
-1,981
| -0.3% | -$101K | 0.19% | 93 |
|
|
2023
Q4 | $36.2M | Sell |
705,207
-678,275
| -49% | -$35.6M | 0.2% | 92 |
|
|
2023
Q3 | $80.3M | Buy |
1,383,482
+261,063
| +23% | +$16M | 0.49% | 44 |
|
|
2023
Q2 | $71.8M | Buy |
1,122,419
+481,035
| +75% | +$32.3M | 0.44% | 48 |
|
|
2023
Q1 | $44.5M | Sell |
641,384
-247,947
| -28% | -$17.5M | 0.27% | 71 |
|
|
2022
Q4 | $64M | Sell |
889,331
-13,790
| -2% | -$1.04M | 0.35% | 63 |
|
|
2022
Q3 | $64.2M | Buy |
903,121
+144,114
| +19% | +$10.5M | 0.33% | 66 |
|
|
2022
Q2 | $58.4M | Sell |
759,007
-33,729
| -4% | -$2.57M | 0.25% | 83 |
|
|
2022
Q1 | $57.9M | Buy |
792,736
+477,281
| +151% | +$32M | 0.23% | 79 |
|
|
2021
Q4 | $19.7M | Buy |
315,455
+110,359
| +54% | +$6.47M | 0.11% | 128 |
|
|
2021
Q3 | $12.1M | Buy |
205,096
+124,879
| +156% | +$8.22M | 0.07% | 175 |
|
|
2021
Q2 | $5.36M | Buy |
80,217
+74,848
| +1,394% | +$4.88M | 0.03% | 323 |
|
|
2021
Q1 | $339K | Buy |
+5,369
| New | +$334K | ﹤0.01% | 409 |
|
|
2020
Q2 | – | Sell |
-69,134
| Closed | -$3.85M | – | 401 |
|
|
2020
Q1 | $3.85M | Buy |
+69,134
| New | +$4.23M | 0.08% | 79 |
|
|
2019
Q4 | – | Sell |
-219,568
| Closed | -$11.1M | – | 483 |
|
|
2019
Q3 | $11.1M | Buy |
+219,568
| New | +$10.3M | 0.1% | 92 |
|
|
2019
Q2 | – | Sell |
-989,293
| Closed | -$47.2M | – | 317 |
|
|
2019
Q1 | $47.2M | Buy |
989,293
+433,770
| +78% | +$21.6M | 0.29% | 19 |
|
|
2018
Q4 | $28.9M | Buy |
555,523
+298,453
| +116% | +$16M | 0.26% | 47 |
|
|
2018
Q3 | $16M | Sell |
257,070
-16,564
| -6% | -$983K | 0.17% | 52 |
|
|
2018
Q2 | $15.1M | Buy |
+273,634
| New | +$14.8M | 0.15% | 54 |
|
|
2017
Q3 | – | Sell |
-131,064
| Closed | -$7.3M | – | 299 |
|
|
2017
Q2 | $7.3M | Buy |
131,064
+34,394
| +36% | +$1.87M | 0.07% | 73 |
|
|
2017
Q1 | $5.26M | Buy |
+96,670
| New | +$5.3M | 0.06% | 92 |
|
|
2016
Q4 | – | Sell |
-390,577
| Closed | -$21.1M | – | 285 |
|
|
2016
Q3 | $21.1M | Buy |
390,577
+204,123
| +109% | +$13.1M | 0.21% | 18 |
|
|
2016
Q2 | $13.7M | Buy |
186,454
+99,609
| +115% | +$7.04M | 0.17% | 43 |
|
|
2016
Q1 | $5.55M | Buy |
86,845
+16,000
| +23% | +$1.01M | 0.07% | 114 |
|
|
2015
Q4 | $4.87M | Buy |
70,845
+51,317
| +263% | +$3.39M | 0.06% | 122 |
|
|
2015
Q3 | $1.16M | Buy |
+19,528
| New | +$1.24M | 0.02% | 229 |
|
|
2014
Q4 | – | Sell |
-10,228
| Closed | -$523K | – | 351 |
|
|
2014
Q3 | $523K | Buy |
+10,228
| New | +$511K | ﹤0.01% | 274 |
|
|
2014
Q2 | – | Sell |
-4,428
| Closed | -$230K | – | 320 |
|
|
2014
Q1 | $230K | Buy |
+4,428
| New | +$236K | ﹤0.01% | 321 |
|
Other funds holding BMY
VCM
VPM
Bridgewater Associates's BMY Position: Q1 2026 in Review
Bridgewater Associates reduced its Bristol-Myers Squibb (BMY) stake by 41% in Q1 2026, selling an estimated $9.75M and leaving 241,689 shares worth $14.7M. The position accounts for 0.07% of the portfolio, ranked #204.
Bridgewater Associates first reported a position in BMY in Q1 2014 and has held it in 36 quarters since. The position peaked at $143M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Bridgewater Associates held 241,689 shares of Bristol-Myers Squibb worth $14.7M as of Q1 2026.
- Bridgewater Associates sold 167,203 Bristol-Myers Squibb shares in Q1 2026, an estimated $9.75M.
- Bristol-Myers Squibb made up 0.07% of Bridgewater Associates's portfolio in Q1 2026, its #204 holding.
- Bridgewater Associates first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 36 quarters since.
- Bridgewater Associates's Bristol-Myers Squibb position peaked at $143M in Q1 2025.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.